ramelteon

ラメルテオン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/31 15:05:23」(JST)

wiki en

[Wiki en表示]

Ramelteon

Systematic (IUPAC) name
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b] furan-8-yl)ethyl]propionamide
Clinical data
Trade names	Rozerem
AHFS/Drugs.com	monograph
MedlinePlus	a605038
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	1.8%
Protein binding	~82%
Metabolism	Hepatic (CYP1A2-mediated)
Half-life	1-2.6 hours
Excretion	Renal (84%) and fecal (4%)
Identifiers
CAS Registry Number	196597-26-9 Y
ATC code	N05CH02
PubChem	CID 10858193
IUPHAR ligand	1356
DrugBank	DB00980 Y
ChemSpider	9033484 Y
UNII	901AS54I69 Y
KEGG	D02689 Y
ChEMBL	CHEMBL133775 Y
Chemical data
Formula	C16H21NO2
Molecular mass	259.343 g/mol
SMILES CCC(NCC[C@@H]1CCC2=CC=C3OCCC3=C12)=O
InChI InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m1/s1  Y Key:YLXDSYKOBKBWJQ-GFCCVEGCSA-N  Y
Y (what is this?)  (verify)

Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of sleep agents that selectively binds to the MT₁ and MT₂ receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABA_A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon. Ramelteon is approved by the U.S. Food and Drug Administration (FDA) for long-term use.

Ramelteon does not show any appreciable binding to GABA_A receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects.

Medical uses

Ramelteon can be used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse, and the withdrawal and rebound insomnia that is typical with GABA modulators is not present in ramelteon. Some clinicians also use ramelteon for the treatment of Delayed sleep phase syndrome.

Ramelteon was recently found to significantly reduce delirium in hospitalized at-risk patients. This multicenter prospective, blinded, randomized, placebo-controlled study found that "Ramelteon was associated with a lower risk of delirium (3% vs 32%; P = .003)". A systematic review, published in 2014, concluded "ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo."

In a double-blind multicenter trial, ramelteon did reduce the time to fall asleep by approximately 15–20 minutes after four weeks compared to placebo (approx. 29-32 versus 48 minutes) Total sleep time improved about 40 minutes, however, this was identical to improvement with placebo at the end of trial. Subjective reported sleep time was greater in ramelteon treated persons. Ramelteon, when compared to placebo, had a much faster onset of effects: one or two weeks. However, the effects were roughly equivalent to placebo at four weeks.

Adverse effects

Six percent of ramelteon-treated patients in clinical trials discontinued due to an adverse event, compared to 2% in the placebo arms. The most frequent adverse events leading to discontinuation were somnolence, dizziness, nausea, fatigue, headache, and insomnia. The United States official Prescribing Information warns of rare cases of anaphylactic reactions, abnormal thinking, and suicide in patients with pre-existing depression.

In mice treated with ramelteon for two years, increases in liver and testicular tumors were observed, but only at doses at least 20x greater than the recommended human dose on a milligram/kilogram basis.

Drug interactions

Ramelteon has been evaluated for potential drug interactions with the following medications and showed no significant effects: omeprazole, theophylline, dextromethorphan, and midazolam, digoxin and warfarin. There were no clinically meaningful effects when ramelteon was coadministered with any of these drugs.

A drug interaction study showed that there were no clinically meaningful effects or an increase in adverse events when ramelteon and the SSRI Prozac (fluoxetine) were coadministered. Ramelteon and fluvoxamine should not be coadministered.

Ramelteon has significant drug-drug interaction with the following drugs: Amiodarone, Ciprofloxacin, Fluvoxamine, Ticlopidine.

Ramelteon should be administered with caution in patients taking other CYP1A2 inhibitors, strong CYP3A4 inhibitors such as ketoconazole, and strong CYP2C9 inhibitors such as fluconazole.

Efficacy may be reduced when ramelteon is used in combination with potent CYP enzyme inducers such as rifampin, since ramelteon concentrations may be decreased.

Mechanism of action

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT₁ and MT₂ receptors and selectivity over the MT₃ receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT₁ or MT₂ receptors, and high selectivity for human MT₁ and MT₂ receptors compared to the MT₃ receptor.

The activity of ramelteon at the MT₁ and MT₂ receptors is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine, and opiates. Ramelteon also does not interfere with the activity of a number of selected enzymes in a standard panel.

The major metabolite of ramelteon, M-II, is active and has approximately one tenth and one fifth the binding affinity of the parent molecule for the human MT₁ and MT₂ receptors, respectively, and is 17 – 25-fold less potent than ramelteon in in vitro functional assays. Although the potency of M-II at MT₁ and MT₂ receptors is lower than the parent drug, M-II circulates at higher concentrations than the parent producing 20 – 100 fold greater mean systemic exposure when compared to ramelteon. M-II has weak affinity for the serotonin 5-HT2B receptor, but no appreciable affinity for other receptors or enzymes. Similar to ramelteon, M-II does not interfere with the activity of a number of endogenous enzymes.

No published studies have indicated whether ramelteon, in humans, is more or less safe or effective than the hormone melatonin which it mimics; melatonin is much less expensive and is widely available over-the-counter in the US and Canada. The biological action of melatonin is similar to that of ramelteon. Ramelteon has been directly compared to melatonin in cats, and Ramelteon had a significant (3x) longer effect and had a more profound effect on the EEG of the sleeping cats.

See also

• Discovery and development of melatonin receptor agonists

References

Sources and external links

• Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder: NCT01677182 on ClinicalTrials.gov
• Kato, K; Hirai, K; Nishiyama, K; Uchikawa, O; Fukatsu, K; Ohkawa, S; Kawamata, Y; Hinuma, S; Miyamoto, M (Feb 2005). "Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.". Neuropharmacology 48 (2): 301–10. doi:10.1016/j.neuropharm.2004.09.007. PMID 15695169. 
• Roth, T; Stubbs, C; Walsh, JK (Mar 2005). "Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment." (PDF). Sleep 28 (3): 303–7. PMID 16173650. 
• Rozerem Official Website
• Prescribing Information Data Sheet
• RxList.com
• Clinical Pharmacokinetic Monitoring of Midazolam in Critically Ill Patients in relation to midazolam as a drug-drug interaction to Rozerem

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 不眠症の治療 treatment of insomnia
• 2. メラトニンの生理学および臨床使用 physiology and available preparations of melatonin
• 3. 認知症患者における睡眠覚醒障害および睡眠障害 sleep wake disturbances and sleep disorders in patients with dementia
• 4. 緩和ケアにおける不眠症の概要 overview of insomnia in palliative care
• 5. せん妄および急性錯乱状態：予防、治療、および予後 delirium and acute confusional states prevention treatment and prognosis

English Journal

• The Effect of Ramelteon on Heartburn Symptoms of Patients With Gastroesophageal Reflux Disease and Chronic Insomnia: A Pilot Study.

• Jha LK1, Fass R, Gadam R, Maradey-Romero C, Nasrollah L, Hershcovici T, Quan SF, Dickman R.
• Journal of clinical gastroenterology.J Clin Gastroenterol.2016 Feb;50(2):e19-24. doi: 10.1097/MCG.0000000000000322.
• BACKGROUND: There is a bidirectional relationship between gastroesophageal reflux disease (GERD) and sleep. It has been demonstrated that antireflux treatment can improve sleep quality in GERD patients with nighttime reflux.MATERIALS AND METHODS: Patients with heartburn and/or regurgitation ≥3 tim
• PMID 25887111

• MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

• Liu J1, Clough SJ1, Hutchinson AJ1, Adamah-Biassi EB1, Popovska-Gorevski M1, Dubocovich ML1.
• Annual review of pharmacology and toxicology.Annu Rev Pharmacol Toxicol.2016 Jan 6;56:361-83. doi: 10.1146/annurev-pharmtox-010814-124742. Epub 2015 Oct 23.
• Melatonin, or 5-methoxy-N-acetyltryptamine, is synthesized and released by the pineal gland and locally in the retina following a circadian rhythm, with low levels during the day and elevated levels at night. Melatonin activates two high-affinity G protein-coupled receptors, termed MT1 and MT2, to e
• PMID 26514204

• Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial.

• Kashihara K1, Nomura T, Maeda T, Tsuboi Y, Mishima T, Takigawa H, Nakashima K.
• Internal medicine (Tokyo, Japan).Intern Med.2016;55(3):231-6. doi: 10.2169/internalmedicine.55.5464. Epub 2016 Feb 1.
• Objective Melatonin is effective for treating patients with rapid eye movement sleep behavior disorder (RBD). Ramelteon, a novel hypnotic, acts as a melatonin receptor agonist. In the current study, we investigated the effects of ramelteon on sleep disorders, including RBD, in patients with Parkinso
• PMID 26831015

Japanese Journal

• Postoperative delirium after pharyngolaryngectomy with esophagectomy : a role for ramelteon and suvorexant

• Esophagus : official journal of the Japan Esophageal Society 14(3), 229-234, 2017-07
• NAID 40021255140

• 脳卒中発症後の睡眠障害に対するラメルテオンの有効性と安全性の検討

• 日本医師会雑誌 = The Journal of the Japan Medical Association 145(11), 2401-2406, 2017-02
• NAID 40021086234

• Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug–Drug Interaction

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 40(12), 2024-2037, 2017
• NAID 130006235451

Related Links

• Ramelteon - Wikipedia, the free encyclopedia

Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABA A ...

Related Pictures

---

★リンクテーブル★

リンク元

「ラメルテオン」

「ラメルテオン」

　　[★]

英

ramelteon

商

ロゼレム

関

その他の中枢神経系用薬